Friday, June 21, 2013

3-V Biosciences Finds $20M

Menlo Park-based 3-V Biosciencs, a biopharmaceuticals firm developing therapeutics for the oncology and infectious disease area, said Friday that it has raised $20M in a series C funding. The funding came from existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates. 3-V said the funding will go towards advancing its lead oncology candidate to Phase 1 clinical trials. 3-V Biosciences is led by Merdad Parsey. More information »